Trial Profile
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Omaveloxolone (Primary)
- Indications Radiation-induced skin damage
- Focus Therapeutic Use
- Acronyms PRIMROSE
- Sponsors Reata Pharmaceuticals
- 15 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 31 Mar 2015 Planned End Date changed from 1 May 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov record.
- 31 Mar 2015 Planned primary completion date changed from 1 Mar 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov record.